AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28162127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4343
Study 25119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the long posterior sacroiliac ligament
Number of subjects: 34
Study 25119510 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection on the contralateral side
Number of subjects: 34
Study 23117188 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg once daily)
Number of subjects: 3091
Study 23117188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3091
Study 22085683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone
Number of subjects: 0
Study 22085683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunct to pharmacotherapy
Number of subjects: 0
Study 22085683 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study 19062151 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (OS) adhesive at 55 degrees C
Number of subjects: 28
Study 19062151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (S3) adhesive at 55 degrees C
Number of subjects: 28
Study 19062151 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) adhesive at 55 degrees C
Number of subjects: 28
Study 19062151 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2 (AB) adhesive at 55 degrees C
Number of subjects: 28
Study 19062151 — intervention group
Group type: COMPARATOR
Intervention: Temperature effect on water sorption and solubility
Number of subjects: 28
Study 16505654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic heat-and-moisture exchanger (HME)
Number of subjects: 381
Study 16505654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-water humidification with a heater wire (DHW)
Number of subjects: 381
Study 16505654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory limb only (SHW)
Number of subjects: 381
Study 16505654 — intervention group
Group type: COMPARATOR
Intervention: HME
Number of subjects: 381
Study 16505654 — intervention group
Group type: COMPARATOR
Intervention: All groups (HME, DHW, SHW)
Number of subjects: 381
Study 12753491 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 18) using the non-dominant leg for 8 weeks during soccer training
Number of subjects: 39
Study 12753491 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 39
Study 12753491 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 18)
Number of subjects: 39
Study 11134834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction
Number of subjects: 88
Study 11134834 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum sodium intake
Number of subjects: 88
Study 9715427 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg for the first week, 50 mg for the second week, and 75 mg nightly thereafter for 12 weeks
Number of subjects: 40
Study 9715427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8602901 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol/sorbitol chewing gum
Number of subjects: 0
Study 8602901 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing gum (stick and pellet forms)
Number of subjects: 0
Study 8602901 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol gum
Number of subjects: 0
Study 2737169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sip-feed supplements
Number of subjects: 0
Study 2737169 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliant patients (who failed to receive supplements)
Number of subjects: 0
Study 2737169 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented patients
Number of subjects: 0
Study 2737169 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented patients
Number of subjects: 0
Study 30990792 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (40% to 60% of heart rate reserve) for 8 weeks
Number of subjects: 87
Study 30990792 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care, education for foot care, and diet (control group)
Number of subjects: 87
Study 29048185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 125
Study 29048185 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 125
Study 29048185 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity measured by Barratt Impulsiveness Scale (BIS)
Number of subjects: 125
Study 29048185 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity measured by Experiential Discounting Task (EDT)
Number of subjects: 125
Study 25261385 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercises (40 minutes, 3 times per week for 6 months)
Number of subjects: 127
Study 25261385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 127
Study 23490008 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar transurethral resection of the prostate (M‐TURP)
Number of subjects: 295
Study 23490008 — intervention group
Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 295
Study 21683321 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR101 4 g/day
Number of subjects: 229
Study 21683321 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR101 2 g/day
Number of subjects: 229
Study 21683321 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR101 4 g/day (baseline TG >750 mg/dl)
Number of subjects: 229
Study 21683321 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR101 2 g/day (baseline TG >750 mg/dl)
Number of subjects: 229
Study 21683321 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR101
Number of subjects: 229
Study 21683321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 19390542 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/HCTZ 12.5 mg (titrated to losartan 100 mg/HCTZ 12.5 mg at 4 weeks and losartan 100 mg/HCTZ 25 mg at 8 weeks)
Number of subjects: 430
Study 19390542 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/HCTZ 12.5 mg
Number of subjects: 430
Study 19390542 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/HCTZ combination therapy
Number of subjects: 430
Study 16887481 — intervention group
Group type: EXPERIMENTAL
Intervention: Left thoracoabdominal approach (LTA)
Number of subjects: 167
Study 16887481 — intervention group
Group type: COMPARATOR
Intervention: Abdominal-transhiatal approach (TH)
Number of subjects: 167
Study 15572179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 and 2 mg on two successive days)
Number of subjects: 42
Study 15572179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11263603 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma irradiation (192Ir)
Number of subjects: 100
Study 11263603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9413769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure (CRF) patients
Number of subjects: 0
Study 8351862 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 51
Study 8351862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg/day)
Number of subjects: 51
Study 29800131 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time model-generated personalized melanoma risk assessment and tailored melanoma-prevention advice
Number of subjects: 272
Study 29800131 — intervention group
Group type: COMPARATOR
Intervention: Generic melanoma-prevention advice
Number of subjects: 272
Study 27600795 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor® 4 g/day
Number of subjects: 253
Study 27600795 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor® 2 g/day
Number of subjects: 253
Study 27600795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 26068602 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV (tegafur-uracil with leucovorin) administered at 300 mg/m²/day with 75 mg/day for 5 courses (5 weeks each)
Number of subjects: 1720
Study 26068602 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1720
Study 23800669 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery 4-7 days after last fraction of radiotherapy
Number of subjects: 1242
Study 23800669 — intervention group
Group type: COMPARATOR
Intervention: Surgery 0-3 days after last fraction of radiotherapy
Number of subjects: 1242
Study 23800669 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Number of subjects: 1242
Study 23800669 — intervention group
Group type: COMPARATOR
Intervention: Interval groups comparison
Number of subjects: 1242
Study 21804100 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fixed-dose combination tablets (ibuprofen 400 mg/paracetamol 1000 mg)
Number of subjects: 892
Study 21804100 — intervention group
Group type: EXPERIMENTAL
Intervention: One fixed-dose combination tablet (ibuprofen 200 mg/paracetamol 500 mg)
Number of subjects: 892
Study 21804100 — intervention group
Group type: EXPERIMENTAL
Intervention: One combination tablet (ibuprofen 200 mg/paracetamol 500 mg)
Number of subjects: 892
Study 21804100 — intervention group
Group type: EXPERIMENTAL
Intervention: Two combination tablets (ibuprofen 400 mg/paracetamol 1000 mg)
Number of subjects: 892
Study 21804100 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1000 mg)
Number of subjects: 892
Study 21804100 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 892
Study 19165707 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 30
Study 19165707 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 30
Study 19165707 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A or B
Number of subjects: 30
Study 17206894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with supracostal access
Number of subjects: 72
Study 17206894 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine nephrostomy tube placement
Number of subjects: 72
Study 12962764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-drug therapy (tacrolimus and corticosteroids)
Number of subjects: 475
Study 12962764 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug therapy (tacrolimus, azathioprine, and corticosteroids)
Number of subjects: 475
Study 11236241 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive exercise test (group I, 78 patients)
Number of subjects: 243
Study 11236241 — intervention group
Group type: COMPARATOR
Intervention: Negative exercise test (group II, 165 patients)
Number of subjects: 243
Study 8621832 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB radiation
Number of subjects: 1
Study 8621832 — intervention group
Group type: COMPARATOR
Intervention: UVA radiation
Number of subjects: 1
Study 8621832 — intervention group
Group type: COMPARATOR
Intervention: Combination UVB/UVA phototherapy
Number of subjects: 1
Study 8621832 — intervention group
Group type: COMPARATOR
Intervention: Heat associated with phototherapy
Number of subjects: 1
Study 1458618 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine
Number of subjects: 50
Study 1458618 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study 6530538 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (50 mmol daily)
Number of subjects: 20
Study 6530538 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (300 mmol daily)
Number of subjects: 20
Study 6530538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous frusemide administration
Number of subjects: 20
Study 6530538 — intervention group
Group type: COMPARATOR
Intervention: Regular sodium intake
Number of subjects: 20
Study 30659039 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of refined wheat bread enriched with 6 g of wheat germ
Number of subjects: 55
Study 30659039 — intervention group
Group type: COMPARATOR
Intervention: Control (non-enriched bread)
Number of subjects: 55
Study 30078420 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 209
Study 30078420 — intervention group
Group type: COMPARATOR
Intervention: Headphone group
Number of subjects: 209
Study 30078420 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study 25808921 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment using reliable change confidence intervals
Number of subjects: 0
Study 25808921 — intervention group
Group type: COMPARATOR
Intervention: Patient-matched healthy controls
Number of subjects: 0
Study 25205802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 449
Study 25205802 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 449
Study 25205802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled cohort (TAVR, n=220; standard therapy, n=229)
Number of subjects: 449
Study 22828688 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine (dexmedetomidine group)
Number of subjects: 90
Study 22828688 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine and 25 μg fentanyl (dexmedetomidine= group)
Number of subjects: 90
Study 22828688 — intervention group
Group type: COMPARATOR
Intervention: 10 mg bupivacaine 0.5% (control group)
Number of subjects: 90
Study 20131980 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% shampoo (CP shampoo)
Number of subjects: 168
Study 20131980 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 168
Study 17105818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 2090
Study 17105818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2090
Study 15942752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution three-dimensional magnetic resonance imaging (MRI) of the vestibular organ
Number of subjects: 0
Study 12486428 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rosuvastatin
Number of subjects: 477
Study 12486428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 477
Study 12486428 — intervention group
Group type: COMPARATOR
Intervention: 20 mg pravastatin
Number of subjects: 477
Study 12486428 — intervention group
Group type: COMPARATOR
Intervention: 20 mg simvastatin
Number of subjects: 477
Study 12486428 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (5 mg and 10 mg)
Number of subjects: 477
Study 12486428 — intervention group
Group type: COMPARATOR
Intervention: pravastatin
Number of subjects: 477
Study 12486428 — intervention group
Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 477
Study 9578099 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoped insoles
Number of subjects: 33
Study 9578099 — intervention group
Group type: COMPARATOR
Intervention: Langer insoles
Number of subjects: 33
Study 8133086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and didanosine (ddI)
Number of subjects: 50
Study 8133086 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine only
Number of subjects: 50
Study 8133086 — intervention group
Group type: COMPARATOR
Intervention: Didanosine (ddI) only
Number of subjects: 50
Study 2546026 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐methylformamide (N‐MF)
Number of subjects: 144
Study 2546026 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirogermanium
Number of subjects: 144
Study 2546026 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐demethoxydaunorubicin
Number of subjects: 144
Study 241115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing iron medicines
Number of subjects: 6
Study 241115 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% aqueous sucrose solution
Number of subjects: 6
Study 241115 — intervention group
Group type: COMPARATOR
Intervention: Iron medicines with sorbitol
Number of subjects: 6
Study 31816169 — intervention group
Group type: EXPERIMENTAL
Intervention: LA + DCB
Number of subjects: 117
Study 31816169 — intervention group
Group type: COMPARATOR
Intervention: LA + BA
Number of subjects: 117
Study 31118099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN) alone
Number of subjects: 139
Study 31118099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN) + Methotrexate (MTX)
Number of subjects: 139
Study 31118099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PDN) + Cyclosporine (CSA)
Number of subjects: 139
Study 31118099 — intervention group
Group type: COMPARATOR
Intervention: Reference group (PDN discontinued)
Number of subjects: 139
Study 31118099 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes
Number of subjects: 139
Study 27918724 — intervention group
Group type: EXPERIMENTAL
Intervention: telotristat ethyl 250 mg
Number of subjects: 135
Study 27918724 — intervention group
Group type: EXPERIMENTAL
Intervention: telotristat ethyl 500 mg
Number of subjects: 135
Study 27918724 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study 27918724 — intervention group
Group type: EXPERIMENTAL
Intervention: telotristat ethyl 250 mg and 500 mg
Number of subjects: 135
Study 25479736 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tPCS
Number of subjects: 30
Study 25479736 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 24165068 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch massage
Number of subjects: 20
Study 24165068 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 24165068 — intervention group
Group type: COMPARATOR
Intervention: Touch massage and Control group
Number of subjects: 20
Study 22074836 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of the mucosa covering retained teeth
Number of subjects: 40
Study 22074836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, only observation)
Number of subjects: 40
Study 19715434 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Number of subjects: 30
Study 19715434 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium oxalate gel
Number of subjects: 30
Study 19715434 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 16924983 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & rinse systems (Single Bond; SB and Scotchbond Multi‐Purpose Plus; SBMP)
Number of subjects: 30
Study 16924983 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etch systems (Clearfil SE Bond; SE, Optibond Solo Plus Self‐Etch Primer; SO, Tyrian Self Priming Etchant + One Step Plus; TY)
Number of subjects: 30
Study 16924983 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step etch & rinse system
Number of subjects: 30
Study 16924983 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching adhesive systems
Number of subjects: 30
Study 15176128 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex aural stimuli
Number of subjects: 11
Study 15176128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempo and sound volume level of aural stimuli
Number of subjects: 11
Study 15176128 — intervention group
Group type: COMPARATOR
Intervention: No-stimulus
Number of subjects: 11
Study 10728365 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 I.U. of recombinant human growth hormone (GH) for 3 months
Number of subjects: 50
Study 10728365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8957033 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 34)
Number of subjects: 69
Study 8957033 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs (n = 35)
Number of subjects: 69
Study 1554449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal dilator
Number of subjects: 11
Study 3575131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg i.m. of Phytonadione (Konakion, Roche) administered on the initial day of GFD
Number of subjects: 37
Study 3575131 — intervention group
Group type: COMPARATOR
Intervention: No vitamin K administration (Control group)
Number of subjects: 37
Study 3575131 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Vitamin K and Control)
Number of subjects: 37
Study 31327235 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive staff-resident interactions
Number of subjects: 341
Study 31327235 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral staff-resident interactions
Number of subjects: 341
Study 31327235 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative staff-resident interactions
Number of subjects: 341
Study 31106951 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt punch
Number of subjects: 10
Study 31106951 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrated punch
Number of subjects: 10
Study 31106951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp punch
Number of subjects: 10
Study 26733351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (one ComProbi capsule containing L. rhamnosus a day)
Number of subjects: 66
Study 26733351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule of placebo a day)
Number of subjects: 66
Study 26095854 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback‐assisted relaxation training
Number of subjects: 0
Study 26095854 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25454870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine, IL-2, GM-CSF and rhGH (n=3)
Number of subjects: 12
Study 25454870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine alone (n=4)
Number of subjects: 12
Study 25454870 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2, GM-CSF and rhGH (n=5)
Number of subjects: 12
Study 25454870 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 12
Study 22965757 — intervention group
Group type: EXPERIMENTAL
Intervention: High PUFA diet (P/S ratio 2:1)
Number of subjects: 16
Study 22965757 — intervention group
Group type: COMPARATOR
Intervention: Low PUFA diet (P/S ratio 0.5:1)
Number of subjects: 16